150 Signet Drive
Tel: 416-749-9300 or 800-268-4623
83 articles about Apotex
Apotex Inc. is pleased to announce that it has received a Drug Shortage Assistance Award from the U.S. Food and Drug Administration (FDA) in recognition of the company's substantial efforts to resolve a shortage of varenicline tablets.
Apotex Inc. is recalling one lot of APO-Amitriptyline 10 mg tablets due to the presence of N-nitrosodimethylamine (NDMA), a nitrosamine impurity, above the acceptable limit.
An affiliate of funds advised by SK Capital Partners, LP (“SK Capital”) announced today that it has reached an agreement to acquire Apotex Pharmaceutical Holdings Inc.
Apotex Inc. is recalling four additional lots of Apo-Acyclovir tablets, in 200 mg and 800 mg strengths, due to the presence of a nitrosamine impurity above or close to the acceptable level.
Apotex Inc., Canada's leading pharmaceutical manufacturer of generic medicines, announced today the launch of APO-ApixabanTM tablets, Canada's first generic alternative to Eliquis®.
Apotex Inc., Canada's leading pharmaceutical manufacturer of generic medicines, announced the Canadian launch of APO-Teriflunomide™ tablets, a generic version of Aubagio®, for the treatment of relapsing remitting multiple sclerosis.
Apotex Inc. is recalling certain lots of Apo-Acyclovir tablets, in 200 mg and 800 mg strengths, due to the presence of a nitrosamine impurity above the acceptable level.
Information Update - Update: Certain lots of Elavil (amitriptyline) and APO-Amitriptyline recalled due to a nitrosamine impurity
AA Pharma Inc. is recalling two lots of Elavil and Apotex Inc. is recalling one additional lot of APO-Amitriptyline 10 mg tablets due to the presence of NDMA, a nitrosamine impurity, above the acceptable limit.
Voluntary Nationwide Recall: One Lot of Mirvala 28 (desogestrel and Ethinyl Estradiol Tablets, Usp) 0.150 Mg / 0.030 Mg Due to Possibility of One Placebo Pill in Place of An Active Pill
Apotex Inc. is conducting a voluntary nationwide recall of one lot of Mirvala™ 28 (Desogestrel and Ethinyl Estradiol Tablets, USP) from wholesalers, distributors, retailers, pharmacies, and consumers.
Canada's largest pharmaceutical manufacturer, Apotex Inc., announced the Canadian launch of the generic version of Revlimid capsules, APO-lenalidomide for the treatment of multiple myeloma and Myelodysplastic syndrome.
RedHill Biopharma Ltd. today announced that RedHill Biopharma Inc., AstraZeneca AB and AstraZeneca Pharmaceuticals LP ("AstraZeneca") and Nektar Therapeutics have entered into a settlement and license agreement with Apotex, Inc. resolving their patent litigation.
Government of Canada Awards Apotex Inc. a Significant Contract to Supply a Safety Net of Additional Dexamethasone in Canada
As Canadians remain impacted by the spread of COVID-19, Apotex, Canada's largest pharmaceutical company has been awarded a contract with the Government of Canada to supply the Critical Drug Reserve of Dexamethasone tablets in response to the COVID-19 pandemic.
Two weeks after announcing concerns about high-levels of carcinogens in popular diabetes drugs, the U.S. Food and Drug Administration announced the first voluntary recalls of this class of drugs manufactured by five companies.
Chiesi Farmaceutici S.p.A. and Apotex, Inc. announced that Chiesi Group has finalized an agreement for the acquisition of the worldwide rights to Ferriprox®.
Chiesi Farmaceutici S.p.A., an international research-focused healthcare Group and Apotex, Inc., together with its US subsidiary, ApoPharma USA Inc., an innovative drug company, active in the hematology and neurodegeneration therapeutic areas, announced that Chiesi Group has finalized an agreement for the acquisition of the worldwide rights to Ferriprox®.
Canada's leading generic drug manufacturer, Apotex, announced today that its first shipment of the drug tamoxifen has been released to the Canadian market
Health Canada is providing Canadians with an update on the supply of tamoxifen, a breast cancer drug, and information on efforts to resolve the national shortage as quickly as possible, recognizing the potentially significant impact that the shortage could have on patients.
Information Update - Health Canada requests that companies stop distributing ranitidine drugs in Canada while it assesses NDMA; additional products being recalled
Health Canada recently informed Canadians that it is assessing the issue of an impurity called N-nitrosodimethylamine (NDMA) detected in some ranitidine drugs.
CORRECTING and REPLACING Alcoholic Hepatitis Treatment Market Worth USD 570 Million, at 6% CAGR during 2019-2023 | Technavio
According to Technavio Research Report "Alcoholic Hepatitis Treatment Market by type (corticosteroids, xanthine derivatives, and others), and geographic regions (North America, Europe, Asia, and ROW) is witnessed to grow by USD 570 million, at a CAGR of 6% from 2019 to 2023”.
Purdue, Bristol-Myers Squibb and Apotex have been singled out in opioid-related lawsuits in Canada.